Ascendis Pharma A/S (Nasdaq: ASND) today announced new data showing improvements in growth and bone morphometry from Week 52 ...

Ascendis Pharma A/S (Nasdaq: ASND) today announced new data showing improvements in growth and bone morphometry from Week 52 of its pivotal ApproaCH ...

Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision ...

Metastatic colorectal cancer (mCRC) continues to pose a clinical and commercial challenge, with low 5-year survival rates and limited durable respons ...

Once-monthly efimosfermin alfa prescribed for metabolic dysfunction–associated steatohepatitis with F2 and F3 fibrosis ...

The Manila Times is one of the leading national broadsheets in the Philippines. It is also one of the oldest, having been founded in 1898. PR Newswire ...

Gastric cancer, the fifth most common malignancy worldwide and the fifth most common cause of cancer-related death, is ...

which in turn crosstalk with ERBB receptors on cancer cells to drive growth. Mutualistic cancer-fibroblast crosstalk mechanisms, identified from patient samples, were verified across in vitro model ...

"This is the first time we've seen improvement in fibrosis that was observed in participants with compensated cirrhosis due ...

The vitamin D receptor activator (VDRA ... patients treated with VDRAs might result from stimulation of fibroblast growth factor 23 (FGF-23) production by these agents. 6 VDRAs can be used ...